| Literature DB >> 35719459 |
Mandeep Kumar1, Neeru Sahni1, Nusrat Shafiq2, Lakshmi Narayana Yaddanapudi1.
Abstract
Introduction: The WHO launched a 5-year global initiative to address the problem of medication errors on March 29, 2017, targeting a decrease in severe and avoidable medication-related harm by 50% in all the countries. Since prescription errors are preventable, this study was conducted to determine incidence and severity of medication prescription errors (MPEs). Settings and design: Intensive care unit of a tertiary care academic hospital, prospective observational study. Methods and materials: For all patients admitted in a medical ICU, baseline data (demographic, APACHE II, length of ICU stay, and days of mechanical ventilation) were noted. Treatment charts were reviewed daily, and each prescription was compared against a master chart prepared using standardized references to study the incidence of prescription errors. Severity classification was done using National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) classification. Mean and median, along with standard deviation and interquartile range, were calculated for all quantitative variables. Multivariate linear regression analysis model was used.Entities:
Keywords: Critically ill; Intensive care unit; Medication errors; Prescription
Year: 2022 PMID: 35719459 PMCID: PMC9160616 DOI: 10.5005/jp-journals-10071-24148
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Severity of MPEs—classification according to the NCCMERP[5]
| Errors with no harm | Category A | Circumstances that have the capacity to cause error |
| Category B | Error did not reach the patient because it was intercepted before or during the administration process | |
| Category C | Error reached the patient but did not cause patient harm | |
| Errors, potential preventable MPEs | Category D | Error reached the patient and required monitoring to confirm that it resulted in no harm to the patient and/or required intervention to preclude harm |
| Errors with preventable MPEs | Category E | Error may have contributed to or result in temporary harm to the patient and required intervention |
| Category F | Error may have contributed to or result in temporary harm to the patient and required initial or prolonged hospitalization |
Flowchart 1Study flowchart
Fig. 1Violin plots for demographic parameters
MPEs and their severity (numbers and percentages)
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Antibiotics | 3,210 | 698 | 26.6 | 89 | 609 | 0.4 | 2.5 |
| Antiviral | 75 | 0 | 0 | 0 | 0 | 0 | 0 |
| Antifungal | 410 | 138 | 5.2 | 52 | 86 | 0.2 | 0.4 |
| Antihypertensive | 527 | 55 | 2.1 | 55 | 0 | 0.2 | 0 |
| Cardiovascular | 699 | 91 | 3.4 | 82 | 9 | 0.3 | 0 |
| Nutrition and general care | 16,353 | 1,510 | 57.6 | 1,367 | 143 | 5.6 | 0.6 |
| Miscellaneous | 1,630 | 60 | 2.2 | 52 | 8 | 0.2 | 0 |
| Steroids and immunosuppressants | 413 | 42 | 1.6 | 35 | 7 | 0.1 | 0 |
| Antiepileptics | 919 | 16 | 0.6 | 13 | 3 | 0.1 | 0 |
| Decongestants | 265 | 10 | 0.3 | 8 | 2 | 0 | 0 |
| Sedatives | 71 | 4 | 0.1 | 4 | 0 | 0 | 0 |
| Total | 24,572 | 2,624 | 100 | 1,757 | 867 | 7.2 | 3.5 |
Fig. 2Violin plots for total drugs and total MPEs
Results of linear regression model for MPEs (independent variable) and patients’ characteristics (dependent variables)
|
|
|
|
|
|
|---|---|---|---|---|
| Intercept | −5.070 | 6.227 | −0.814 | 0.417 |
| Age | −0.015 | 0.049 | −0.299 | 0.766 |
| Gender: Male–Female | 2.304 | 1.890 | 1.219 | 0.225 |
| Weight | −0.045 | 0.077 | −0.584 | 0.560 |
| Weekend: 1–0 | −0.907 | 1.715 | −0.529 | 0.598 |
| ICU days | 0.451 | 0.329 | 1.373 | 0.172 |
| Ventilation days | 0.039 | 0.346 | 0.112 | 0.911 |
| Comorbidity: 1–0 | −1.153 | 1.746 | −0.661 | 0.510 |
| Outcome: Death–discharge | 3.667 | 2.105 | 1.742 | 0.084 |
|
| 2.082 | 0.576 | 3.612 | <0.001 |
| Hemoglobin | 0.236 | 0.343 | 0.687 | 0.493 |
|
| 3.799 | 1.664 | 2.282 | 0.024 |
| PaO2/FiO2 ratio | 0.004 | 0.006 | 0.632 | 0.528 |
SE, standard error